Biomarkers in the assessment of therapies for familial amyloidotic polyneuropathy

Molecular Medicine

Volumn 13, Issue 11-12, 2007, Pages 584-591

  Macedo, Bárbara ^a,b   Batista, Ana Rita ^a   Do Amaral, José Barbas ^c   Saraiva, Maria João ^a,b  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c HOSPITAL DE SANTO ANTÓNIO   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ALDEHYDE; BIOLOGICAL MARKER; CASPASE 8; DEATH RECEPTOR; GLUTAREDOXIN; HYDROXYNONENAL; PREALBUMIN; PROTEIN BAX; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DNA DAMAGE; FAMILIAL AMYLOID POLYNEUROPATHY; HOMEOSTASIS; HUMAN; HUMAN TISSUE; IMMUNIZATION; LIPID PEROXIDATION; MOUSE; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROPHYLAXIS; TRANSGENIC MOUSE;

AMYLOIDOSIS, FAMILIAL; ANIMALS; ANIMALS, GENETICALLY MODIFIED; APOPTOSIS; BIOLOGICAL MARKERS; DNA DAMAGE; IMMUNOHISTOCHEMISTRY; MICE; OXIDATIVE STRESS; POLYNEUROPATHIES; PREALBUMIN;

EID: 36849096153     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/2007-00068.Macedo     Document Type: Article

References (27)

1. Andrade C.(1952) A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of peripheral nerves. Brain 75:408-27.
2. Coimbra A, Andrade C. (1971) Familial amyloid polyneuropathy, an electron microscope study of the peripheral nerve in five cases. Brain 94:199-212.
3. Saraiva MJ. (2001) Transthyretin mutations in hyperthyroxinemia and amyloid diseases. Hum. Mutat. 17:493-503.
4. Saraiva MJ, Birken S, Costa PP, Goodman DS. (1984) Amyloid fibril protein in familial amyloidotic polyneuropathy, Portuguese type: definition of molecular abnormality in transthyretin (prealbumin). J. Clin. Invest. 74:104-19.
5. Sebastião MP, Saraiva MJ, Damas AM. (1998) The crystal structure of amyloidogenic Leu55.Pro transthyretin variant reveals a possible pathway for transthyretin polymerization into amyloid fibrils. J. Biol. Chem. 273:24715-22.
6. Quintas A, Vaz DC, Cardoso I, Saraiva MJ, Brito RM. (2001) Tetramer dissociation and monomer partial unfolding precedes protofibril formation in amyloidogenic transthyretin variants. J. Biol. Chem. 276:27207-13.
7. Sousa MM, Cardoso I, Fernandes R, Guimarães A, Saraiva MJ. (2001) Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: evidence for toxicity of nonfibrillar aggregates. Am. J. Pathol. 159:1993-2000.
8. Sousa MM, Du Yan S, Fernandes R, Guimaraes A, Stern D, Saraiva MJ. (2001) Familial amyloid polyneuropathy: receptor for advanced glycation end products-dependent triggering of neuronal inflammatory and apoptotic pathways. J. Neurosci. 21:7576-86.
9. Teixeira PF, Cerca F, Santos SD, Saraiva MJ. (2006) Endoplasmic reticulum stress associated with extracellular aggregates: evidence from transthyretin deposition in familial amyloid polyneuropathy. J. Biol. Chem. 281:21998-2003.
10. Sousa MM, Fernandes R, Palha JA, Taboada A, Vieira P, Saraiva MJ. (2002) Evidence for early cytotoxic aggregates in transgenic mice for human transthyretin Leu55Pro. Am. J. Pathol. 161:1935-48.
11. Terazaki H, Ando Y, Fernandes R, Yamamura K, Maeda S, Saraiva MJ. (2006) Immunization in familial amyloidotic polyneuropathy: counteracting deposition by immunization with a Y78F TTR mutant. Lab. Invest. 86:23-31.
12. Santos SD, Saraiva MJ. (2005) Proceedings of the Society for Neuroscience 35th annual meeting. Program No. 670.9, Abstract Viewer and Itinerary Planner, Society for Neuroscience, Washington, D. C. November 12-16.
13. Sousa MM, do Amaral JB, Guimaraes A, Saraiva MJ. (2005) Up-regulation of the extracellular matrix remodeling genes, biglycan, neutrophil gelatinase-associated lipocalin, and matrix metalloproteinase-9 in familial amyloid polyneuropathy. FASEB J. 19:124-6.
14. Mattson MP. (2004) Pathways toward and away from Alzheimer's disease. Nature 430:631-9.
15. Ando Y, Nyhlin N, Suhr O, et al. (1997) Oxidative stress is found in amyloid deposits in systemic amyloidosis. Biochem. Biophys. Res. Commun. 232:497-502.
16. Akterin S, Cowburn RF, Miranda-Vizuete A, et al. (2006) Involvement of glutaredoxin-1 and thioredoxin-1 in beta-amyloid toxicity and Alzheimer's disease. Cell Death Differ. 13:1454-1465.
17. Zong WX, Li C, Hatzivassiliou G, Lindsten T, Yu QC, Yuan J, Thompson CB. (2003) Bax and Bak can localize to the endoplasmic reticulum to initiate apoptosis. J. Cell. Biol. 162:59-69.
18. Bieschke J, Zhang Q, Powers ET, Lerner RA, Kelly JW. (2005) Oxidative metabolites accelerate Alzheimer's amyloidogenesis by a two-step mechanism, eliminating the requirement for nucleation. Biochemistry 44:4977-83.
19. Leanderson P, Tagesson C. (1992) Rapid and sensitive detection of hydroxyl radicals formed by activated neutrophils in the presence of chelated iron, hydroxylation of deoxyguanosine to 8-hydroxydeoxyguanosine. Agents Actions 36:50-7.
20. Arner ES, Holmgren A. (2000) Physiological functions of thioredoxin and thioredoxin reductase. Eur. J. Biochem. 267:6102-9.
21. Xu J, Chen S, Ku G, et al. Amyloid beta peptide-induced cerebral endothelial cell death involves mitochondrial dysfunction and caspase activation. J. Cereb. Blood Flow Metab. 21:702-10.
22. Ashkenazi A. (2002) Targeting death and decoy receptors of the tumor-necrosis factor superfamily. Nat. Rev. Cancer 2:420-30.
23. Strasser A, O'Connor L, Dixit VM. (2000) Apoptosis signaling. Ann. Rev. Biochem. 69:217-45.
24. Cagnol S, Van Obberghen-Schilling E, Chambard JC. (2006) Prolonged activation of ERK1,2 induces FADD-independent caspase 8 activation and cell death. Apoptosis 11:337-46.
25. Monteiro FA, Sousa MM, Cardoso I, do Amaral JB, Guimaraes A, Saraiva MJ. (2006) Activation of ERK1/2 MAP kinases in familial amyloidotic polyneuropathy. J. Neurochem. 97:151-61.
26. Cain K. (2003) Chemical-induced apoptosis: formation of the Apaf-1 apoptosome. Drug Metab. Rev. 35:337-63.
27. Angelin A, Tiepolo T, Sabatelli P, et al. (2007) Mitochondrial dysfunction in the pathogenesis of Ullrich congenital muscular dystrophy and prospective therapy with cyclosporins. Proc. Natl. Acad. Sci. USA. 104: 991-6.